Bogaards JA - Search Results

1

Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia.

Goudsmit J, Bogaards JA, Jurriaans S, Schuitemaker H, Lange JM, Coutinho RA, Weverling GJ. Goudsmit J, et al. Among authors: bogaards ja. AIDS. 2002 Mar 29;16(5):791-3. doi: 10.1097/00002030-200203290-00016. AIDS. 2002. PMID: 11964537 No abstract available.

2

Health and economic effects of introducing single-dose or two-dose human papillomavirus vaccination in India.

M de Carvalho T, Man I, Georges D, Saraswati LR, Bhandari P, Kataria I, Siddiqui M, Muwonge R, Lucas E, Sankaranarayanan R, Basu P, Berkhof J, Bogaards JA, Baussano I. M de Carvalho T, et al. Among authors: bogaards ja. BMJ Glob Health. 2023 Nov;8(11):e012580. doi: 10.1136/bmjgh-2023-012580. BMJ Glob Health. 2023. PMID: 37931940 Free PMC article.

3

Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis.

Bogaards JA, Weverling GJ, Geskus RB, Miedema F, Lange JM, Bossuyt PM, Goudsmit J. Bogaards JA, et al. Antivir Ther. 2003 Feb;8(1):43-50. Antivir Ther. 2003. PMID: 12713063

4

AIDS vaccines that allow HIV-1 to infect and escape immunologic control: a mathematic analysis of mass vaccination.

van Ballegooijen M, Bogaards JA, Weverling GJ, Boerlijst MC, Goudsmit J. van Ballegooijen M, et al. Among authors: bogaards ja. J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):214-20. doi: 10.1097/00126334-200310010-00012. J Acquir Immune Defic Syndr. 2003. PMID: 14526211

5

Meeting the immense need for HAART in resource-poor settings.

Bogaards JA, Goudsmit J. Bogaards JA, et al. J Antimicrob Chemother. 2003 Nov;52(5):743-6. doi: 10.1093/jac/dkg454. Epub 2003 Oct 16. J Antimicrob Chemother. 2003. PMID: 14563896 Review. No abstract available.

6

Is population-level perversity a likely outcome of mass vaccination against HIV?

Bogaards JA, van Ballegooijen WM, Jan Weverling G, Boerlijst MC, Goudsmit J. Bogaards JA, et al. Lancet Infect Dis. 2005 May;5(5):254; author reply 255-6. doi: 10.1016/S1473-3099(05)70089-X. Lancet Infect Dis. 2005. PMID: 15854875 No abstract available.

7

Plasma HIV-1 RNA to guide patient selection for antiretroviral therapy in resource-poor settings: efficiency related to active case finding.

Bogaards JA, Weverling GJ, Zwinderman AH, Bossuyt PM, Goudsmit J. Bogaards JA, et al. J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):232-7. doi: 10.1097/01.qai.0000179457.46809.42. J Acquir Immune Defic Syndr. 2006. PMID: 16394857

8

A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells.

Marzio G, Kerkvliet E, Bogaards JA, Koelewijn S, De Groot A, Gijsbers L, Weverling GJ, Vogels R, Havenga M, Custers J, Pau MG, Guichoux JY, Lewis J, Goudsmit J. Marzio G, et al. Among authors: bogaards ja. Vaccine. 2007 Mar 8;25(12):2228-37. doi: 10.1016/j.vaccine.2006.12.011. Epub 2006 Dec 28. Vaccine. 2007. PMID: 17250936

9

The potential of targeted antibody prophylaxis in SARS outbreak control: a mathematic analysis.

Bogaards JA, Putter H, Jan Weverling G, Ter Meulen J, Goudsmit J. Bogaards JA, et al. Travel Med Infect Dis. 2007 Mar;5(2):70-8. doi: 10.1016/j.tmaid.2006.01.007. Epub 2006 May 5. Travel Med Infect Dis. 2007. PMID: 17298911 Free PMC article.

10

A sensitive cell-based assay for the detection of residual infectious West Nile virus.

Koldijk MH, Bogaards JA, Kostense S, de Vocht M, Gijsbers L, Ter Haak M, Ophorst C, Brakenhoff JP, Weverling GJ, Guichoux JY, Uytdehaag F, Lewis J, Goudsmit J, Marzio G. Koldijk MH, et al. Among authors: bogaards ja. Vaccine. 2007 Sep 28;25(39-40):6872-81. doi: 10.1016/j.vaccine.2007.07.011. Epub 2007 Jul 27. Vaccine. 2007. PMID: 17707954

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

83 results

Search Page